RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+14.02%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.23B
AUM Growth
+$1.23B
(+9%)
Cap. Flow
-$32.4M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$23.6M |
| 2 |
Teladoc Health
TDOC
|
$23M |
| 3 |
Johnson & Johnson
JNJ
|
$18.1M |
| 4 |
Merck
MRK
|
$15.1M |
| 5 |
Royalty Pharma
RPRX
|
$12.5M |
Top Sells
| 1 |
NovoCure
NVCR
|
$50.1M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$25.9M |
| 3 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$23.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$20.6M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$18.8M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Industrials | 0.53% |
| 3 | Communication Services | 0% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $53.6M | 4.37% | 500,000 +220,000 | +79% | +$23.6M |
|
|
2
BioMarin Pharmaceuticals
BMRN
$11.2B
| $44.7M | 3.65% | 510,000 -234,354 | -31% | -$20.6M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $43.9M | 3.58% | 600,000 -95,000 | -14% | -$6.95M |
|
4
Medtronic
MDT
$119B
| $37.5M | 3.06% | 320,000 +99,220 | +45% | +$11.6M |
|
5
UnitedHealth
UNH
$281B
| $36.8M | 3% | 105,000 -5,000 | -5% | -$1.75M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $36.3M | 2.96% | 220,000 +50,000 | +29% | +$8.25M |
|
7
Eli Lilly
LLY
$657B
| $30.4M | 2.48% | 180,000 +15,000 | +9% | +$2.53M |
|
8
Cigna
CI
$80.3B
| $29.1M | 2.38% | 140,000 -10,000 | -7% | -$2.08M |
|
9
CVS Health
CVS
$92.8B
| $28.7M | 2.34% | 420,000 +180,000 | +75% | +$12.3M |
|
|
10
Merck
MRK
$210B
| $28.1M | 2.3% | 344,020 +184,020 | +115% | +$15.1M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $27.2M | 2.22% | 115,000 +5,000 | +5% | +$1.18M |
|
12
Elevance Health
ELV
$71.8B
| $25.7M | 2.1% | 80,000 -10,000 | -11% | -$3.21M |
|
13
Humana
HUM
$36.5B
| $23.8M | 1.94% | 58,000 -2,000 | -3% | -$821K |
|
|
14
Teladoc Health
TDOC
$1.37B
| $23M | 1.88% | +115,000 | New | +$23M |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $23M | 1.87% | 460,000 | – | – |
|
16
Nektar Therapeutics
NKTR
$568M
| $23M | 1.87% | 1,350,000 +350,000 | +35% | +$5.95M |
|
17
Gilead Sciences
GILD
$140B
| $22.4M | 1.83% | 385,000 +95,000 | +33% | +$5.53M |
|
|
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22M | 1.79% | 100,000 -14,311 | -13% | -$3.14M |
|
19
Guardant Health
GH
$8.41B
| $21.9M | 1.79% | 170,000 -70,000 | -29% | -$9.02M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $21.1M | 1.72% | 340,000 +50,000 | +17% | +$3.1M |
|
|
21
NovoCure
NVCR
$1.38B
| $20.8M | 1.69% | 120,000 -289,600 | -71% | -$50.1M |
|
|
XLRN
22
DELISTED
Acceleron Pharma Inc.
XLRN
| $20.5M | 1.67% | 160,000 +15,000 | +10% | +$1.92M |
|
|
ABMD
23
DELISTED
Abiomed Inc
ABMD
| $20.4M | 1.67% | 63,000 -7,000 | -10% | -$2.27M |
|
|
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $20.1M | 1.64% | 235,000 -75,000 | -24% | -$6.43M |
|
25
Cooper Companies
COO
$13.4B
| $20M | 1.63% | 55,000 -5,000 | -8% | -$1.82M |
|